Related Experiment Video
Updated: Jul 3, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Remission in psoriatic arthritis
1University Hospitals Leuven, Division of Rheumatology, Herestraat 49, B-3000 Leuven, Belgium. kurt.devlam@uzleuven.be
Current Rheumatology Reports
|July 30, 2008
Summary
Psoriatic arthritis (PsA) treatment has improved with anti-tumor necrosis factor agents, making remission a possible goal. However, specific tools to define PsA remission are currently unavailable and need development.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition linked to psoriasis, often causing joint damage and disability.
- Historically, PsA treatment options were limited, with a low chance of remission or cure.
- The advent of anti-tumor necrosis factor (TNF) agents has significantly improved both joint and skin symptoms in PsA patients.
Purpose of the Study:
- To highlight the impact of anti-TNF therapy on PsA treatment goals.
- To address the current lack of specific assessment tools for PsA remission.
- To advocate for the development and integration of new remission criteria into clinical practice.
Main Methods:
- This section is not applicable as the abstract does not detail specific methods but rather discusses the evolution of treatment and future needs.
Main Results:
- Anti-TNF therapies have substantially improved articular and cutaneous manifestations of PsA.
- The success of TNF blockers has elevated treatment expectations, making remission a more realistic objective.
Conclusions:
- Achieving remission is now a viable goal in managing psoriatic arthritis.
- There is an urgent need for validated instruments to define and measure remission in PsA.
- Future clinical trials and registries should incorporate novel assessments for PsA remission.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...